ImmunoCellular Therapeutics, Ltd’s Dendritic Cell-Based Vaccine Demonstrates Statistically Significant Increase in Survival in an Animal Model of Glioblastoma

LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (OTC.BB: IMUC) announced today that its dendritic cell-based vaccination with cancer stem cells (CSCs) demonstrated a statistically significant survival benefit in a preclinical animal model of glioblastoma. The rats were either immunized with cancer stem cells (CSCs) from a brain cancer tumor or the daughter cells (the bulk of the tumor), and results showed that those immunized with the CSCs had a median survival of 50 days compared to 29 days for daughter cells. Furthermore, 30% of animals vaccinated against cancer stem cells demonstrated long term survival as compared to animals vaccinated with the bulk of the tumor, all of which died.

MORE ON THIS TOPIC